Theradiag Announces Its Revenue for the First Half Of 2020

Regulatory News:

THERADIAG (Paris:ALTER) (ISIN: FR0004197747, Ticker: ALTER), a company specializing in in vitro diagnostics and Theranostics, today announces its consolidated half-year revenue and cash position at June 30, 2020, data that is currently being audited.

Consolidated H1 2020 revenue of €4.9 million

In thousands of euros		June 30, 2020		June 30, 2019		Change
Revenue*		4,871		4,976		-2.1%
of which Theranostics		2,410		2,070		+16.5%
of which LISA TRACKER kits in routine use		2,410		2,041		+18.1%
of which IVD		2,367		2,906		-18.6%
*Data currently being audited

Over the six months to June 30, 2020, Theradiag generated revenue of €4.9 million, versus €5.0 million in the first half of 2019 highlighting the robustness and quality of the products marketed despite a delicate economic and health situation.

The Theranostics business posted another half of solid growth, with revenue up +16.5%, primarily driven by sales of LISA TRACKER kits in routine use whose sales exceeded €2.4 million in the first half of 2020 (vs. €2.0 million at June 30, 2019). As has been the case for a number of semesters now, the Theranostics represents the Company’s recurring business, thus providing it with enhanced visibility.